Vadastuximab tedelpar antibody-drug conjugate representing a significant advancement in the approach of acute myeloid leukemia (AML). This pioneering therapy precisely targets CD33, a protein frequently found https://mediajx.com/story27892654/vadastuximab-a-deep-examination-into-cd33-specific-therapy